Abstract:Background: Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease characterized by painful nodules, drainage and scarring in skin folds. Injectable adalimumab is the only drug approved by the US Food and Drug Administration for the treatment of HS. Although systemic Janus kinase (JAK) inhibitors show promise, serious side-effects have been reported. There are no highly effective topical treatments for HS; furthermore, the contribution of epidermal keratinocytes to the intense inflammation has largely been unexplored. Objectives: We investigated the role of keratinocytes and epidermal immune cells in HS inflammation at all Hurley stages of disease severity. We aimed to determine whether ruxolitinib can mitigate inflammation from keratinocytes and to develop a better understanding of how topical therapeutics might benefit patients with HS. Methods: We used skin samples from 87 patients with HS (Hurley stages I-III) and 39 healthy controls to compare keratinocyte- and immune cell-driven epidermal inflammation, in addition to the response of lesional HS keratinocytes to treatment with interferon (IFN)-γ and ruxolitinib. We used haematoxylin and eosin staining, immunohistochemistry, immunoblotting and quantitative reverse-transcription polymerase chain reaction assessments in whole skin, isolated epidermis, and cultured keratinocytes from healthy controls and both nonlesional and lesional HS skin to identify and define epidermal and keratinocyte-mediated inflammation in HS and how this may be targeted by therapeutics. Results: HS lesional keratinocytes autonomously secreted high levels of chemokines, such as CCL2, CCL3 and CXCL3, which recruited neutrophils, CD8 T cells, and natural killer cells to the epidermis. Keratinocytes were the dominant source of tumour necrosis factor-α and interleukin (IL)-6 in HS lesions with little to no contribution from underlying dermal immune cells. In the presence of IFN-γ, which is dependent on immune cell infiltrate in vivo, keratinocytes expressed increased levels of additional cytokines including IL-1β, IL-12, IL-23 and IL-36γ. The JAK inhibitor ruxolitinib mitigated the expression of inflammatory cytokines and chemokines in HS lesional keratinocytes, thus providing a rationale for future study as a topical treatment for HS. Conclusions: This study demonstrates that keratinocytes actively recruit immune cells to HS epidermis and interactions between these cells drive a broad inflammatory profile in HS epidermis. Targeting epidermal inflammation in HS with novel topical formulations may be highly efficacious with reduced systemic side-effects.

Hidradenitis Suppurativa: New Targets and Emerging Treatments

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa

Hidradenitis suppurativa: a review of current treatment options

Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution

The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review

The most recent advances in understanding and managing hidradenitis suppurativa

Cytokine-Mediated Molecular Pathophysiology of Hidradenitis Suppurativa: A Narrative Review

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials

An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa

Hidradenitis suppurativa: a new therapeutic approach for an old disease

Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management—A Systematic Review

Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?

Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies

Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment

Bimekizumab for the treatment of hidradenitis suppurativa

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data